1. Antimicrobial resistance (AMR) is a major health threat, causing more than 700,000 deaths annually and projected to increase to 10 million by 2050.
2. COVID-19 has impacted antimicrobial drug management activities and driven AMR in various ways due to the increased use of antibiotics and secondary bacterial infections in COVID-19 patients.
3. Probiotics have been shown to regulate the host's immune response to SARS-CoV-2, restore microbial balance, and improve outcomes or reduce long-term complications in COVID-19 patients.
This article provides an overview of the impact of antibiotics and probiotics on the gut antimicrobial resistance gene reservoir in COVID-19 patients. The article is based on a study that included 142 patients with confirmed SARS-CoV-2 infection who were followed up for 9 months after virus clearance. The study found that antibiotic-naive COVID-19 patients had significantly higher levels of ARGs than non-COVID-19 controls, suggesting that all COVID-19 patients who were antibiotic naive were susceptible to ARGs. Furthermore, the study showed that probiotics may reduce the number of ARGs accumulated during COVID-19 disease in antibiotic naive individuals.
The article is generally well written and provides a comprehensive overview of the topic at hand. It includes relevant citations from other studies which support its claims and provide evidence for its conclusions. However, there are some potential biases that should be noted when evaluating this article’s trustworthiness and reliability. Firstly, it does not explore any counterarguments or alternative perspectives on the issue at hand which could provide a more balanced view of the topic. Secondly, it does not discuss any potential risks associated with using probiotics as a treatment for COVID-19 which could be important for readers to consider before making decisions about their own health care choices. Finally, it does not present both sides equally; instead it focuses mainly on the benefits of using probiotics as a treatment for COVID-19 without providing an equal amount of information about potential drawbacks or risks associated with this approach.